Literature DB >> 11961113

Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.

Sean Ekins1, Richard B Kim, Brenda F Leake, Anne H Dantzig, Erin G Schuetz, Lu-Bin Lan, Kazuto Yasuda, Robert L Shepard, Mark A Winter, John D Schuetz, James H Wikel, Steven A Wrighton.   

Abstract

P-glycoprotein (P-gp) is an efflux transporter involved in limiting the oral bioavailability and tissue penetration of a variety of structurally divergent molecules. A better understanding of the structural requirements of modulators of P-gp function will aid in the design of therapeutic agents. Toward this goal, three-dimensional quantitative structure-activity relationship (3D-QSAR) models were generated using in vitro data associated with inhibition of P-gp function. Several approaches were undertaken with multiple iterations, yielding Catalyst 3D-QSAR models being able to qualitatively rank-order and predict IC(50) values for P-gp inhibitors excluded from the model in question. The success of these validations suggests that a P-gp pharmacophore for 27 inhibitors of digoxin transport in Caco-2 cells consisted of four hydrophobes and one hydrogen bond acceptor. A second pharmacophore generated with 21 inhibitors of vinblastine binding to plasma membrane vesicles derived from CEM/VLB(100) cells contained three ring aromatic features and one hydrophobic feature. A third pharmacophore generated with 17 inhibitors of vinblastine accumulation in P-gp expressing LLC-PK1 cells contained four hydrophobes and one hydrogen bond acceptor. A final pharmacophore was generated for inhibition of calcein accumulation in P-gp expressing LLC-PK1 cells and found to contain two hydrophobes, a ring aromatic feature, and a hydrogen bond donor. The similarity of features for the pharmacophores of P-gp inhibitors of digoxin transport and vinblastine binding suggest some commonality in their binding sites. Utilization of such models may prove to be of value for prediction of molecules that may modulate one or more P-gp binding sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961113     DOI: 10.1124/mol.61.5.964

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

Review 1.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

2.  Quantitative structure-activity relationship and quantitative structure-pharmacokinetics relationship of 1,4-dihydropyridines and pyridines as multidrug resistance modulators.

Authors:  Xiao-Fei Zhou; Qingxiang Shao; Robert A Coburn; Marilyn E Morris
Journal:  Pharm Res       Date:  2005-09-20       Impact factor: 4.200

Review 3.  Recent progress in the computational prediction of aqueous solubility and absorption.

Authors:  Stephen R Johnson; Weifan Zheng
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 4.  Pharmacophore-based discovery of ligands for drug transporters.

Authors:  Cheng Chang; Sean Ekins; Praveen Bahadduri; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

Review 5.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 6.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

7.  Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1.

Authors:  Lucy J Martínez-Guerrero; Mark Morales; Sean Ekins; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2016-07-14       Impact factor: 4.436

Review 8.  Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition.

Authors:  P Bhatia; M Kolinski; R Moaddel; K Jozwiak; I W Wainer
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

9.  Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.

Authors:  Charles R Yates; Cheng Chang; Jeffrey D Kearbey; Kazuto Yasuda; Erin G Schuetz; Duane D Miller; James T Dalton; Peter W Swaan
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

10.  In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Christophe Rousselle; Marcel Debray; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.